Ultimovacs ASA announced that Carlos de Sousa, MD, has been appointed as the new Chief Executive Officer. Dr. de Sousa joins Ultimovacs as a seasoned industry executive with 30 years of experience ranging from leadership positions at international pharmaceutical companies such as Pfizer, Novartis and Nycomed/Takeda, to executive management roles at several innovative biotech companies. Dr. de Sousa will commence as CEO on 1 June 2020. Until then, Øyvind Kongstun Arnesen will continue in his position as CEO. On 1 June 2020, Arnesen will start as a consultant in the evergreen investment firm Radforsk, the same firm that established Ultimovacs together with Inven2.